Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-beta 1a and SARS coronavirus replication.

Lisa E Hensley1, Lisa E Fritz, Peter B Jahrling

  • 1Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702, USA.

Emerging Infectious Diseases
|March 20, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mpox Seroprevalence among Sex Workers and Men who have Sex with Men Preceding Sustained Urban Outbreak in the Democratic Republic of the Congo.

Epidemiology and infection·2026
Same author

Bundibugyo Ebola in DR Congo and Uganda: community-centred response must be operational, not rhetorical.

The Lancet. Infectious diseases·2026
Same author

Implementation of a One Health Surveillance System in the Democratic Republic of the Congo.

EcoHealth·2026
Same author

Assessing mpox knowledge and sexual behaviours within high-risk populations in the Democratic Republic of the Congo.

BMJ global health·2026
Same author

Optimization of environmental air sampling for viral metagenomics in a cave-roosting bat assemblage.

One health outlook·2026
Same author

Equine sentinels and one health: a comprehensive serological survey of Crimean-Congo hemorrhagic fever virus in southeastern and Central Europe.

Frontiers in veterinary science·2026
Same journal

Detection of and Early Genomic Insights into Chikungunya Virus, Bolivia, 2025.

Emerging infectious diseases·2026
Same journal

Household Transmission of Enterovirus D68, Washington and Oregon, United States, 2022-2024.

Emerging infectious diseases·2026
Same journal

New World Ocular Dirofilariasis Caused by Dirofilaria repens Infection, United States.

Emerging infectious diseases·2026
Same journal

Angiostrongylus cantonensis Rat Lungworm Detected in Rats, Madagascar, 2022-2023.

Emerging infectious diseases·2026
Same journal

Human Pulmonary Dirofilariasis,
North Queensland, Australia, 2023<sup>1</sup>.

Emerging infectious diseases·2026
Same journal

Trends in Congenital Syphilis Cases by Maternal Country of Birth, Spain, 2016-2024.

Emerging infectious diseases·2026
See all related articles

Recombinant human interferon-beta 1a effectively inhibits SARS coronavirus replication in laboratory settings. This finding offers a potential therapeutic avenue for severe acute respiratory syndrome (SARS).

Area of Science:

  • Virology
  • Infectious Diseases
  • Public Health

Background:

  • The 2003 global outbreak of severe acute respiratory syndrome (SARS) was caused by a novel coronavirus.
  • SARS presented a critical public health challenge due to its rapid spread and significant morbidity and mortality.
  • Limited effective treatments for SARS necessitated the urgent search for antiviral therapies.

Purpose of the Study:

  • To investigate the antiviral potential of recombinant human interferon-beta 1a against SARS-associated coronavirus (SARS-CoV).

Main Methods:

  • In vitro assays were employed to assess the efficacy of recombinant human interferon-beta 1a.
  • SARS-CoV replication was measured in the presence of the drug.

Main Results:

Related Experiment Videos

  • Recombinant human interferon-beta 1a demonstrated potent inhibition of SARS-CoV replication.
  • The study confirmed the antiviral activity of interferon-beta 1a against the SARS virus in a controlled laboratory environment.

Conclusions:

  • Recombinant human interferon-beta 1a shows significant promise as an antiviral agent against SARS-CoV.
  • Further research into interferon-beta 1a may lead to effective treatments for severe acute respiratory syndrome.